iVeena Overview

  • Founded

  • 2006

Founded
  • Status

  • Private

  • Employees

  • 5

Employees
  • Latest Deal Type

  • Grant

  • Latest Deal Amount

  • $1.68M

  • Investors

  • 7

iVeena General Information

Description

Developer of medical technologies designed to treat ophthalmic diseases. The company's technology includes post-surgery cataract inflammation, macular degeneration (wet AMD), diabetic retinopathy, and glaucoma and it uses novel approaches including drug delivery from the lens capsule, enabling doctors to treat eye infections effectively.

Contact Information

Website
www.iveenamed.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Delivery
Other Industries
Drug Discovery
Primary Office
  • 391 Chipeta Way
  • Suite I
  • Salt Lake City, UT 84108
  • United States
+1 (801) 000-0000

iVeena Timeline

2020202120222023
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

iVeena Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Grant 31-Aug-2022 $1.68M 00.000 Completed Clinical Trials - General
8. Grant 31-Jul-2021 000 00.000 Completed Clinical Trials - General
7. Later Stage VC (Series B) 08-Jul-2020 00.000 00.000 000.00 Completed Clinical Trials - General
6. Grant 29-Sep-2018 00000 00.00 Completed Clinical Trials - General
5. Grant 30-Jun-2018 00000 00.00 Completed Clinical Trials - General
4. Later Stage VC (Series A1) 04-Dec-2017 00.00 00.00 000.00 Completed Clinical Trials - General
3. Accelerator/Incubator 00.00 Completed Clinical Trials - General
2. Later Stage VC (Series A) 12-Jul-2016 $1.3M $1.3M 00.00 Completed Clinical Trials - General
1. Grant 31-Dec-2015 $217K Completed Clinical Trials - General
To view iVeena’s complete valuation and funding history, request access »

iVeena Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series B 0,000,000 00.000000 00.00 00.00 00 00.00 0.000
Series A-1 0,000,000 00.000000 00.00 00.00 00 00.00 00.00
Series A 2,190,000 $0.000100 $1 $1 1x $1 13.87%
To view iVeena’s complete cap table history, request access »

iVeena Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of medical technologies designed to treat ophthalmic diseases. The company's technology includes post-surgery
Drug Delivery
Salt Lake City, UT
5 As of 2023
00.000
0000000000 00.000

000000

t aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in vol
0000 00000000
00 As of 0000
000.00
0000000000 0 000.00

000000

p ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate v
0000 000000000
Paris, France
00 As of 0000
0000
00.00 0000-00-00
00000000000 0000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

iVeena Competitors (6)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
TearClear Venture Capital-Backed 00 000.00 0000000000 0 000.00
000000000 Venture Capital-Backed Paris, France 00 0000 00000000000 0000
000 000000000000 Venture Capital-Backed Ann Arbor, MI 00 000.00 00000000000 000.00
0000000 Venture Capital-Backed Cambridge, United Kingdom 00 00.000 00000000000 00.000
000000 00000000000 Formerly VC-backed Bedford, MA 000 00000 000000 - 000 00000
To view iVeena’s complete competitors history, request access »

iVeena Executive Team (9)

Name Title Board Seat Contact Info
Gerald Simmons Chief Executive Officer and Board Member
Ned Weinshenker Ph.D Chief Operating Officer & Board Member
Balamurali Ambati Founder, Board Member & President
Michael Burr Vice President, Product Development
Sarah Molokhia Ph.D Vice President, Research & Development
You’re viewing 5 of 9 executive team members. Get the full list »

iVeena Board Members (10)

Name Representing Role Since
Amir Shojaei Ph.D Self Board Member 000 0000
Balamurali Ambati iVeena Founder, Board Member & President 000 0000
Barry Hanover iVeena Board Member 000 0000
Gerald Simmons iVeena Chief Executive Officer and Board Member 000 0000
James Jensen JD iVeena Chairman of the Board 000 0000
You’re viewing 5 of 10 board members. Get the full list »

iVeena Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

iVeena Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Mountain Pacific Venture Partners Venture Capital Minority 000 0000 000000 0
National Science Foundation Government 000 0000 000000 0
Park City Angels Angel Group Minority 000 0000 000000 0
SLC Angels Angel Group Minority 000 0000 000000 0
University of Utah Research Foundation Angel Group Minority 000 0000 000000 0
You’re viewing 5 of 7 investors. Get the full list »

Ready to get started?

Request a free trial